156 results on '"Widmark, Anders"'
Search Results
2. Investigating microRNA Profiles in Prostate Cancer Bone Metastases and Functional Effects of microRNA-23c and microRNA-4328
3. Suppl FigS3 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
4. Suppl FigS2 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
5. Suppl FigS5 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
6. Suppl FigS2 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
7. Suppl FigS4 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
8. Suppl FigS1 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
9. Suppl FigS1 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
10. Suppl FigS5 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
11. Suppl FigS6 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
12. Table S3 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
13. Suppl FigS6 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
14. Suppl FigS4 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
15. Table S2 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
16. Suppl FigS3 from The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
17. Hyaluronic acid spacer in prostate cancer radiotherapy: dosimetric effects, spacer stability and long-term toxicity and PRO in a phase II study
18. IDENTIFICATION OF INTRA-PROSTATIC LESIONS USING PSMA, ACETATE-PET AND MPMRI
19. PROSTATE CANCER RISK CLASSIFICATION FROM MULTIPARAMETRIC MRI AND PET IMAGE DATA EVALUATED BY REGISTERED HISTOPATHOLOGY
20. Epithelial and Stromal Characteristics of Primary Tumors Predict the Bone Metastatic Subtype of Prostate Cancer and Patient Survival after Androgen-Deprivation Therapy
21. Patient (pt) population and radiation therapy (RT) type in the long-term phase 3 double-blind, placebo (PBO)-controlled ATLAS study of apalutamide (APA) added to androgen deprivation therapy (ADT) in high-risk localized or locally advanced prostate cancer (HRLPC).
22. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
23. Clinical and biological relevance of the transcriptomic‐based prostate cancer metastasis subtypes MetA‐C
24. Paediatric diagnostic reference levels for common radiological examinations using the European guidelines
25. Establishing paediatric diagnostic reference levels using reference curves – A feasibility study including conventional and CT examinations
26. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer
27. High Monocyte Count and Expression of S100A9 and S100A12 in Peripheral Blood Mononuclear Cells Are Associated with Poor Outcome in Patients with Metastatic Prostate Cancer
28. Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo
29. Registration of histopathology to magnetic resonance imaging of prostate cancer
30. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
31. In Reply to Sari et al
32. Abstract B08: Tumor-educated platelets for early prostate cancer diagnosis, and therapy stratification in patients with metastasized castration resistant prostate cancer
33. Erectile Dysfunction and Absorbed Dose to Penile Base Structures in a Randomized Trial Comparing Ultrahypofractionated and Conventionally Fractionated Radiation Therapy for Prostate Cancer
34. Radical radiotherapy for prostate cancer: patterns of care in Sweden 1998–2016
35. Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial
36. Comparative Effectiveness of Different Radical Radiotherapy Treatment Regimens for Prostate Cancer: A Population-Based Cohort Study
37. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti‐androgens
38. Assessing Radiographic Response to 223Ra with an Automated Bone Scan Index in Metastatic Castration-Resistant Prostate Cancer Patients
39. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial
40. Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor
41. Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
42. The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
43. Abstract B025: The proteome of prostate cancer bone metastases
44. Abstract A048: Bone remodeling in relation to androgen receptor activity in prostate cancer bone metastases
45. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer
46. Past and present work practices of European interventional cardiologists in the context of radiation protection of the eye lens—results of the EURALOC study
47. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity
48. Prostate Cancer Death After Radiotherapy or Radical Prostatectomy: A Nationwide Population-based Observational Study
49. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial
50. Osteoblast-derived factors promote metastatic potential in human prostate cancer cells, in part via non-canonical transforming growth factor β (TGFβ) signaling
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.